Business news

Peptides and Heparin Market will Reach Revenues Worth US$ 35,000 Million by 2031

By Supriya Bhor

Posted on February 22, 2022

Peptides are short chains of amino acids linked together by peptide bonds. Peptides are molecules that are commonly referred to as proteins, and the functions of which are determined by the amino acid sequence and size.

Heparin is a disaccharide anticoagulant, also known as a blood thinner, that prevents blood clots from forming. Heparin is produced by mast cells and basophils in the body, and it is stored in mast cells and secreted wherever injuries occur.

The global peptide and heparin market is expected to grow at a high single-digit CAGR over the forecast period, according to Fact.MR (2021-2031). By the end of 2026, the peptide and heparin market is expected to generate nearly US$ 35,000 million in revenue.

Market Taxonomy

Region North America
Latin America
Europe
Japan
APEX
MENU

Product Type Sodium Heparin
Ammonium Heparin
lithium Heparin
Icatibant
Bivalirudin
Liraglutide
Exenatide
Goserelin
Bortezomib
Other Product Types

Route of Administration Intravenous
Oral Route
Others

Indication Diabetes
Cardiovascular
Cancer
Metabolic Disorder
Central Nervous Systems
Other Indications

Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Competition Monitoring

Because of the large number of international and regional vendors, the global market for peptides and heparin is highly fragmented and competitive.

These companies are constantly working on generic formulations for blood coagulation and a variety of other novel therapeutic areas.

Companies that can produce drugs that are effective at treating coagulation disorders and have high efficacy and safety profiles are likely to gain the most market share shortly.

Key market participants identified by the report include